Mabwell Signs Licensing Deals With Southeast Asia Partners for Aflibercept Biosimilar 9MW0813 in Philippines, Vietnam, and Malaysia
Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062, HKG: 2493) announced that it has entered into...
Mabwell Bioscience
Mabwell (Shanghai) Bioscience Secures NMPA Approval for 9MW5211 Clinical Trials in Primary Biliary Cholangitis
Mabwell (Shanghai) Bioscience Co., Ltd. (HKG: 2493) announced that China’s National Medical Products Administration (NMPA)...
Mabwell Secures NMPA IND Approval for 9MW5211 Injection in Vitiligo, Expanding Multi-Indication Autoimmune Pipeline with Highly Selective Depleting Antibody
Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced that its Investigational New Drug (IND) application...
Mabwell Bioscience Secures NMPA Approval for 9MW5211 Antibody in Type 1 Diabetes, Expanding Autoimmune Pipeline
Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062, HKG: 2493) announced that its clinical trial application...
Mabwell Bioscience Secures NMPA Approval for 9MW5211 Clinical Trial in Multiple Sclerosis – Expanding Autoimmune Pipeline
Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced that China’s National Medical Products Administration (NMPA)...
Mabwell Secures NMPA Clinical Trial Approval for 6MW5311 Bispecific Antibody – Dual US-China Authorization for Hematological Malignancies
Mabwell Bioscience Co., Ltd. (HKG: 2493) announced that China’s National Medical Products Administration (NMPA) has...
Mabwell Bioscience Presents Promising Phase I/II Data for Nectin-4 ADC Bulumtatug Fuvedotin in Cervical Cancer at ESMO-GC
Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced the presentation of compelling clinical data for...
Mabwell Bioscience Secures FDA Approval for 6MW5311 Bispecific Antibody Trial in Hematologic Malignancies
Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced that the U.S. Food and Drug Administration...
Mabwell Bioscience Secures NMPA Clinical Approval for 9MW5211 in Inflammatory Bowel Disease – Highly Specific Depleting Antibody Targets Pathogenic Immune Cells
Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced it has received clinical trial approval from...
Mabwell Bioscience Secures Second NMPA Approval for Denosu Biosimilar, Expanding Indication to Bone Metastases and Multiple Myeloma
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced it has received a second indication approval...
Mabwell Bioscience Secures FDA Clearance for 9MW5211 in IBD, Advances Multi-Indication Autoimmune Pipeline
Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062, HKG: 2493) announced it has received clinical clearance...
Mabwell Bioscience Raises $185 Million in Hong Kong IPO After Two Previous Failed Attempts – Oncology and Age-Related Disease Developer Secures HK$1.45 Billion Valuation
Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062, HKG: 2493) successfully completed its initial public offering...
Mabwell Bioscience Expands Southeast Asia Reach with Malaysian Licensing Deal for Denosumab Biosimilars Rexeva and Denosu
Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has announced a new licensing agreement with a...
Mabwell Bioscience Secures Second NMPA Approval for Denosu, China’s First Xgeva Biosimilar, Expanding Indication to Bone Metastasis and Multiple Myeloma
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced a second indication approval from China’s...
MediTrust Mabwell Insurance Ecosystem Partnership
Shanghai MediTrust Health Technology Group Co., Ltd. (a subsidiary of Shanghai Pharmaceuticals) announced a comprehensive...
Mabwell Partners with Sentonix on Neurodegenerative Disease Drug Discovery Alliance
Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced a global strategic cooperation agreement with Sentonix,...
Mabwell’s SynuSight Licenses PET Tracer 18F-FD4 to ABLi for Parkinson’s Trials
Mabwell (688062.SH) announced that its incubated investment company, SynuSight Biotech, has signed a non‑exclusive clinical...
Mabwell’s 9MW1911 Cuts COPD Exacerbations by 30% in Phase 2a, FDA Accepts US Trial Application
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced that its ST2‑blocking monoclonal antibody 9MW1911 has...
Mabwell Partners with Ping An Health to Launch Integrated Bone‑Health & Autoimmune Care Platform
Mabwell Bioscience (SHA: 688062) disclosed a strategic, deep‑level collaboration with Ping An Healthcare and Technology...
Mabwell’s 9MW3811 Gains NMPA Approval to Launch World‑First IL‑11‑Targeting Phase 2 Trial for Pathological Scarring
Mabwell Bioscience (SHA: 688062) announced that its proprietary monoclonal antibody 9MW3811 has received clearance from...